Shares of oncology-focused biopharmaceutical company Arcus Biosciences, Inc. (RCUS) are trading 15 percent higher on Thursday. The company on Wednesday reported positive clinical activity from its three-arm randomized Phase 2 ARC-7 study.
The company said that the first interim analysis of the three-arm randomized Phase 2 ARC-7 study, with both arms being domvanalimab-based combinations showed encouraging clinical activity when given as a first-line treatment to people with metastatic, non-small cell lung cancer. Arcus Biosciences said that all the trials will continue as planned and data will presented at year-end.
The stock is currently trading at $27.00, up $3.65 or 15% on the NYSE. RCUS has traded between $16.69 and $42.36 during the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.